There are various predictors of irAEs associated with anti-PD-1/PD-L1 therapy in clinical practice, such as BMI, autoimmune disease and neutrophil-to-lymphocyte ratio (11, 12, 14). The gene discussed is PDCD1; the disease is autoimmune disease.